Good thing we are not selling outright. As it says:
(c) “BD Agreement” means a significant licensing arrangement with a pharmaceutical company that will include an initial (“up-front”) payment to the Company in an amount in the double-digits millions of dollars and will arrange for such pharmaceutical company to undertake the continuing development of the Company’s Brilacidin compound in the indication of Oral Mucositis, including the conducting and funding of clinical trials aiming towards the filing of an NDA”
We are unloading BOM for someone else to do the leg work. While ipix collects CASH!
I'm making no guess re pps multiples, but limited resources will be no issue after any deal. The potential of the product, imo, will be the largest pull on pps, not the anemic pps starting point we see.
News 
Market Data 
Discover 
